Biography for Mark Hollmer
Mark Hollmer, Contributing Editor
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene. You can reach him at email@example.com.
Articles by Mark Hollmer
A drug used since the 1960s to treat Type 2 diabetes appears to prolong both life and good health in middle-aged male mice. If further research supports the early results, the discovery could allow doctors to use the drug to stave off metabolic decline in humans as they grow older.
As of today's issue, please welcome Suzanne Elvidge as the new editor for FierceBiotechResearch.
Another preclinical study has generated a promising new Alzheimer's treatment--a synthetic compound developed at the University of Minnesota.
Massachusetts General Hospital/Harvard scientists have developed a new drug candidate that appears to successfully reduce and protect against Huntington's disease damage in two mouse studies. Its target: blocking the activity of SIRT2, an enzyme that regulates a number of cellular functions.
Amgen has an interesting new weapon in the battle against obesity.
Stem cells derived from skeletal muscle helped improve heart function in rats after a heart attack, according to new research by scientists in Norway.
Two long-marketed immunosuppressant drugs, combined into a single compound, effectively treated multiple sclerosis in preclinical studies with effective, targeted results and few side effects.
Scientists at the Texas Biomedical Research Institute have big plans for a new treatment designed to help stop the transmission of HIV. The San Antonio Express-News reports that in January they'll start testing a genetically engineered vaccine in rhesus monkeys that interacts with epithelial stem cells to do its job.
When confronted with an anti-cancer virus, the immune system of a patient with rapidly advancing brain tumors kicks into action, generating natural killer cells to destroy what it sees as an invasion, scientists at Ohio State University and colleagues have found.
McGill University researchers and colleagues discovered a protein abnormality linked to symptoms of autism in mice.